Double-blind randomized comparative trial: ornidazole (Tiberal) versus tinidazole (Fasigin) for the treatment of non-specific vaginitis.
In a double-blind, randomized trial 60 patients with demonstrated bacteriological and clinical non-specific vaginitis were treated with tinidazole versus ornidazole. Thirty patients received tinidazole 2 g daily taken orally in two separate doses for two consecutive days. Twenty-three patients (76%) were cured, 3 patients (10%) relapsed and 4 patients were therapeutic failures. Thirty patients received ornidazole with the same regimen. Twenty-eight patients (93%) were cured, 1 patient (3.3%) relapsed and 1 patient had intolerance to the medication.
D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D009593:Nitroimidazoles / Q000627:therapeutic use*; D009950:Ornidazole / Q000627:therapeutic use*; D014011:Tinidazole / Q000627:therapeutic use*; D014627:Vaginitis / Q000188:drug therapy*
D009593:Nitroimidazoles; D014011:Tinidazole; D009950:Ornidazole